A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 1, 2014, Pages 90-96

  Drake, W M ^a   Stiles, C E ^a   Howlett, T A ^b   Toogood, A A ^c   Bevan, J S ^d   Steeds, R P ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE;

ADENOMA; ADULT; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEART VALVE STENOSIS; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MICROADENOMA; MIDDLE AGED; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY VALVE INSUFFICIENCY; PULMONARY VALVE STENOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION; TRICUSPID VALVE STENOSIS; UNITED KINGDOM; VALVULAR HEART DISEASE;

ADULT; CROSS-SECTIONAL STUDIES; DOPAMINE AGONISTS; ECHOCARDIOGRAPHY; ERGOLINES; ERGOT ALKALOIDS; FEMALE; GREAT BRITAIN; HEART VALVE DISEASES; HUMANS; HYPERPROLACTINEMIA; MALE; MIDDLE AGED; PREVALENCE;

EID: 84892152812     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2254     Document Type: Article

References (24)

1. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356:29-38.
2. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004;363:1179-1183.
3. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med. 2007;356:39-46.
4. Bogazzi F, Buralli S, Manetti L, et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008;62:1864-1869.
5. Colao A, Galderisi M, Di Sarno A, et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93:3777-3784.
6. Kars M, Delgado V, Holman ER, et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93:3348-3356.
7. Lancellotti P, Livadariu E, Markov M, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008; 159:1-5.
8. Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159:R11-R14.
9. Tan T, Cabrita IZ, Hensman D, et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73:369-374.
10. Vallette S, Serri K, Rivera J, et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12:153-157.
11. Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167:17-25.
12. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70:104-108.
13. Lafeber M, Stades AM, Valk GD, et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol. 2010;162:667-675.
14. Nachtigall LB, Valassi E, Lo J, et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72:53-58.
15. British Society of Echocardiography Education Committee. A minimum dataset for a standard transthoracic echocardiogram. http://www.bsecho.org.uk/ tte-minimum-dataset/. Accessed December, 2013.
16. Medicines and Healthcare Products Regulatory Agency. Drug safety update. Ergot-derived dopamine agonists: risk of fibrotic reactions in chronic endocrine uses. http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087807. 2008.
17. Sherlock M, Toogood AA, Steeds R. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart. 2009;95:522-523.
18. Gu H, Luck S, Carroll PV, Powrie J, Chambers J. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin Endocrinol (Oxf). 2011;74:608-610.
19. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez, Sarano M. Burden of valvular heart diseases: a populationbased study. Lancet. 2006;368:1005-1011.
20. Drug Safety Update: Latest Advice for Medicines Users. Ergot-derived dopamine agonists: new warnings and contraindications. Medicines and Healthcare Products Regulatory Agency. http://www.mhra.gov.uk/safetyinformation/ drugsafetyupdate/CON085186. Published July 2008. Accessed December, 2013.
21. Delgado V, Biermasz NR, van ThielS W, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012;77:99-105.
22. Serratrice J, Disdier P, Habib G, Viallet F, Weiller PJ. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002;10:334-336.
23. Lundin L, Norheim I, Landelius J, Oberg K, Theodorsson-Norheim E. Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 1988;77:264-269.
24. Robiolio PA, Rigolin VH, Wilson JS, et al. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation. 1995;92:790-795.